BridgeBio strikes drug royalty deal for cash infusion - BioPharma Dive

Retrieved on: 2024-01-18 16:52:30

Tags for this article:

Therapeutic gene modulation

Alnylam Pharmaceuticals

Leerink Partners

Tafamidis

Royalty payment

Food and Drug Administration

BridgeBio Pharma

Click the tags to see associated articles and topics

BridgeBio strikes drug royalty deal for cash infusion - BioPharma Dive. View article details on HISWAI: https://www.biopharmadive.com/news/bridge-bio-financing-royalties-blue-owl-canada-pension/704881/

Excerpt

The company sold 5% royalties on sales of its drug acoramidis in exchange for $500 million upon FDA approval of the transthyretin amyloidosis ...

Article found on: www.biopharmadive.com

View Original Article